Comparative Pharmacology
Head-to-head clinical analysis: NOVOLOG versus NOVOLOG FLEXTOUCH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOVOLOG versus NOVOLOG FLEXTOUCH.
NOVOLOG vs NOVOLOG FLEXTOUCH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin analog that lowers blood glucose by binding to insulin receptors, enhancing peripheral glucose uptake, and inhibiting hepatic glucose production.
Insulin analog with rapid onset and short duration of action; binds to insulin receptors, promoting cellular glucose uptake and inhibiting hepatic glucose production.
Subcutaneous injection: 0.5-1 unit/kg/day divided into 3 or more doses given within 15 minutes before or after meals. Typical total daily dose range 0.5-1.5 units/kg.
Subcutaneous injection; typical adult dose is 0.5-1 unit/kg/day divided into multiple doses; for type 1 diabetes, administered 5-10 minutes before meals with a basal insulin; for type 2 diabetes, initial dose 4 units or 0.1-0.2 units/kg with meals.
None Documented
None Documented
Terminal elimination half-life is 1.2-1.5 hours in healthy individuals, reflecting rapid clearance. In renal impairment (e.g., eGFR <30 mL/min), half-life may be prolonged up to 2-3 hours due to reduced degradation.
1.5-2 hours (subcutaneous); terminal elimination half-life: 1.8 hours
Renal excretion accounts for approximately 60-80% of insulin aspart degradation products; unchanged drug is minimally excreted. Biliary/fecal excretion is negligible (<10%).
Renal: ~60% as unchanged drug and metabolites; biliary/fecal: ~40%
Category C
Category C
Insulin Analog
Insulin Analog